Our Science

In order to facilitate the infiltration of immune cells into the TME of solid tumor, Cure Genetics equips the NKT cells with strong immune infiltration ability through its proprietary technology platforms.

The presence of numerous immunosuppressive cells makes TME a “cold” immune environment
The physical barrier of solid tumors blocks infiltration of immune cells in TME
Technology
VELP™

VELP™

AAV screening platform-VELP™(Vector Engineering Library Production)
VELP™ platform generates high-quality unbiased AAV capsid plasmid library and minimizes the cross-package of viral library production. The VELP™ AAV libraries are well-balanced and with high genotype-phenotype correlation. The good quality of starting library in directed evolution generates more reliable AAV serotype candidates with organ-specific tropism and excellent safety profile, which will significantly accelerate the development of AAV-based genetic therapies.

Gene Editing Platform-CRISPR

Gene Editing Platform-CRISPR

Optimized CRISPR-Cas gene editing technology by rational design has been applied in developing cell-based therapies.

Pipeline
Therapeutic Area
Cell Therapy
Gene therapy
Indication
Solid Tumor
Rare Genetic Disease
Common Genetic Disease
1231
CGC081
CGC081
1231
CGC082
CGC082
1231
CGG101
CGG101
CGG101
1231
CGG201
CGG201
1231
CGC729(Auto)
CGC729(Auto)
1231
CGC738(Auto)
CGC738(Auto)
1231
CGC766(Auto)
CGC766(Auto)